Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Lastacaft in Allergic Conjunctivitis (CAC Model)
NCT00241319Phase 3Completed
- Start
- Oct 2005
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic conjunctivitis (AC) comparing R89674 0.25% with Placebo (2 arms). Primary endpoints: Ocular itching post challenge and Conjunctival redness post challenge. Started Oct 2005; status: completed.
02
Drugs
alcaftadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT00241319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241319.